Objective： To detect the expression of vascular endothelial growth factor （VEGF） and microvessel density （MVD） count in breast benign affection, breast atypical hyperplasia and breast carcinoma in situ, and to cl...Objective： To detect the expression of vascular endothelial growth factor （VEGF） and microvessel density （MVD） count in breast benign affection, breast atypical hyperplasia and breast carcinoma in situ, and to clarify the relationship between VEGF expression, MVD and the clinicopathological features of these diseases. Methods： The expression of VEGF and MVD count in 115 cases breast benign diseases （including 40 breast fibroid tumor, 40 breast cystic hyperplasia and 35 intraductal papilloma, 19 breast atypical hyperplasias and 32 breast carcinomas in situ were examined by immunohistochemistry staining （SP-method）. Results： The positive rate of VEGF in breast benign diseases, breast atypical hyperplasia and breast carcinoma in situ were 21.74%（25/115）, 31.58.% （6/19）and 53.13%（17/32） respectively. It was the lowest in breast benign affection group, and was the highest breast carcinoma in situ group. The expression of VEGF increased gradually in the three groups （P〈0.05）. The MVD count of the three groups were 14.41 ± 2.59, 18.89± 4.47 and 21.13 ± 4.12 respectively, It was the lowest in breast benign affection group, and was the highest breast carcinoma in situ group. The MVD count of the three groups increased gradually （P〈0.05）. In VEGF positive group, MVD count was 19.41 ±4.78; In VEGF negative group, MVD count was 14.91±3.15. The MVD count was higher in VEGF positive group than that in VEGF negative group （P〈0.05）. Conclusion： The results of this study suggested that VEGF could promote microvessel growth in breast tumors. The occurrence and progression of breast cancer might be related with the expression of VEGF.展开更多
目的探索一种治疗原发性双侧大结节性肾上腺增生(PBMAH)的新方法并分析其疗效。方法回顾性分析郑州大学第一附属医院在2010年3月—2021年4月收治的20例确诊为PBMAH患者的临床资料。20例患者均采用腹腔镜下带蒂肾上腺背部皮下移位术治疗...目的探索一种治疗原发性双侧大结节性肾上腺增生(PBMAH)的新方法并分析其疗效。方法回顾性分析郑州大学第一附属医院在2010年3月—2021年4月收治的20例确诊为PBMAH患者的临床资料。20例患者均采用腹腔镜下带蒂肾上腺背部皮下移位术治疗,术后定期监测患者的临床症状、血浆游离皮质醇、促肾上腺皮质激素(ACTH)、24 h尿游离皮质醇(UFC)。结果术后19例患者获得随访,1例患者失联,随访时间18~120个月,中位值60个月。术后3个月复查血浆游离皮质醇、ACTH、24 h UFC,1例出现血浆游离皮质醇下降、ACTH升高,但患者未出现皮质激素低下症状,观察3个月后复查血浆游离皮质醇、ACTH,均恢复正常。术后6~48个月复查血浆游离皮质醇、ACTH、24 h UFC,19例患者均恢复正常,临床症状消失。结论腹腔镜下带蒂肾上腺背部皮下移位术是治疗PBMAH新的有效治疗方法,可长期缓解库欣综合征患者的症状,目前尚未发现明显不良反应。展开更多
文摘Objective： To detect the expression of vascular endothelial growth factor （VEGF） and microvessel density （MVD） count in breast benign affection, breast atypical hyperplasia and breast carcinoma in situ, and to clarify the relationship between VEGF expression, MVD and the clinicopathological features of these diseases. Methods： The expression of VEGF and MVD count in 115 cases breast benign diseases （including 40 breast fibroid tumor, 40 breast cystic hyperplasia and 35 intraductal papilloma, 19 breast atypical hyperplasias and 32 breast carcinomas in situ were examined by immunohistochemistry staining （SP-method）. Results： The positive rate of VEGF in breast benign diseases, breast atypical hyperplasia and breast carcinoma in situ were 21.74%（25/115）, 31.58.% （6/19）and 53.13%（17/32） respectively. It was the lowest in breast benign affection group, and was the highest breast carcinoma in situ group. The expression of VEGF increased gradually in the three groups （P〈0.05）. The MVD count of the three groups were 14.41 ± 2.59, 18.89± 4.47 and 21.13 ± 4.12 respectively, It was the lowest in breast benign affection group, and was the highest breast carcinoma in situ group. The MVD count of the three groups increased gradually （P〈0.05）. In VEGF positive group, MVD count was 19.41 ±4.78; In VEGF negative group, MVD count was 14.91±3.15. The MVD count was higher in VEGF positive group than that in VEGF negative group （P〈0.05）. Conclusion： The results of this study suggested that VEGF could promote microvessel growth in breast tumors. The occurrence and progression of breast cancer might be related with the expression of VEGF.
文摘目的探索一种治疗原发性双侧大结节性肾上腺增生(PBMAH)的新方法并分析其疗效。方法回顾性分析郑州大学第一附属医院在2010年3月—2021年4月收治的20例确诊为PBMAH患者的临床资料。20例患者均采用腹腔镜下带蒂肾上腺背部皮下移位术治疗,术后定期监测患者的临床症状、血浆游离皮质醇、促肾上腺皮质激素(ACTH)、24 h尿游离皮质醇(UFC)。结果术后19例患者获得随访,1例患者失联,随访时间18~120个月,中位值60个月。术后3个月复查血浆游离皮质醇、ACTH、24 h UFC,1例出现血浆游离皮质醇下降、ACTH升高,但患者未出现皮质激素低下症状,观察3个月后复查血浆游离皮质醇、ACTH,均恢复正常。术后6~48个月复查血浆游离皮质醇、ACTH、24 h UFC,19例患者均恢复正常,临床症状消失。结论腹腔镜下带蒂肾上腺背部皮下移位术是治疗PBMAH新的有效治疗方法,可长期缓解库欣综合征患者的症状,目前尚未发现明显不良反应。
